Abstract Previous studies have shown that cGMPdependent protein kinase (PKG) act on several targets in the contractile pathway to reduce intracellular Ca 2? and/or augment RhoA-regulated myosin light chain phosphatase (MLCP) activity and cause muscle relaxation. Recent studies have identified a novel protein M-RIP that associates with MYPT1, the regulatory subunit of MLCP. Herein, we examine whether PKG enhance MLCP activity downstream of Ca 2? and RhoA via phosphorylation of M-RIP in gastric smooth muscle cells. Treatment of permeabilized muscle cells with 10 lM Ca 2? caused an increase in MLC 20 phosphorylation and muscle contraction, but had no effect on Rho kinase activity. Activators of PKG (GSNO or cGMP) decreased MLC 20 phosphorylation and contraction in response to 10 lM Ca 2? ,
Introduction
Contraction of smooth muscle is dependent on phosphorylation of 20 kDa myosin light chain (MLC 20 ) at Ser 19 , which stimulates the ATPase activity of the smooth muscle myosin [1] [2] [3] . The levels of MLC 20 phosphorylation are regulated by opposing activities of MLC kinase (MLCK) and MLC phosphatase (MLCP). Contractile agonists stimulate MLCK, a Ca 2? /calmodulin-dependent enzyme, mainly by increasing cytosolic Ca 2? and inhibit MLCP. Inhibition of MLCP is mediated via phosphorylation of CPI-17, an endogenous inhibitor of MLCP (MYPT1), by protein kinase C, and the regulatory subunit of MLCP by Rho kinase [1, 2, [4] [5] [6] . MYPT1 acts as a regulator of the catalytic subunit by targeting MLCP to myosin filaments and enhancing substrate specificity toward myosin. The N-terminal of MYPT1 is composed of eight repeat sequences that correspond to the sequences of an ankyrin repeat that are important for regulation and targeting of MLCP. The holoenzyme of MLCP has higher activity than its catalytic subunit suggesting that the binding of the regulatory subunit increases MLCP activity. Phosphorylation of MYPT1 by Rho kinase was shown to dissociate MYPT1 from myosin and hence, may decrease the dephosphorylating activity of MLCP toward myosin [5, 7, 8] .
Recent studies have identified a new protein termed myosin phosphatase-Rho interacting protein (M-RIP) that interact directly and simultaneously with RhoA and MYPT1 and thus, forms a ternary complex [9] [10] [11] [12] [13] [14] . M-RIP lacks a catalytic domain, but contains several proteinprotein interaction domains including two pleckstrin homology domains, two proline-rich sequences, and a C-terminal coiled-coil domain [9] [10] [11] . MYPT1 and RhoA bind on distinct sites of M-RIP and hence do not interfere with each other. RhoA interacting region resides in the first coiled region, whereas MYPT1 interacting region resides in the second/third coiled-coil region [15] . Suppression of M-RIP blocks inhibition of MLCP activity in response to contractile agonist suggesting that M-RIP plays an important role in the regulation of MLCP activity and MLC 20 phosphorylation [6] . M-RIP facilitates the myosin/MLCP interaction and stimulates the activity of the holoenzyme toward myosin without affecting the catalytic subunit alone [16] . The N-terminus of M-RIP binds to actin and thus targets MLCP to the acto-myosin contractile filaments to dephosphorylate myosin [11, 12, 14] . Interaction of MLCP, via leucine zipper domain at C-terminus of MYPT1, with cGMP-dependent protein kinase (PKG) leads to the association of the M-RIP with PKGIa [15, [17] [18] [19] [20] [21] [22] [23] . It is, therefore, conceivable that M-RIP may also be a target of PKGIa. Consistent with this possibility M-RIP is a phosphoprotein and co-precipitates with PKGIa [13, 24] . However, phosphorylation of M-RIP and the regulatory role of phosphorylation are not known. In the present study, we set out to examine the effect of PKG on M-RIPregulated MLCP activity. We show that activation of PKG: (i) increases phosphorylation of M-RIP; (ii) increases the association of M-RIP with MYPT1; (iii) increases MLCP activity, and (iv) decreases Ca 2? -induced MLC 20 phosphorylation and muscle contraction downstream of Ca 2? and RhoA. We conclude that M-RIP is a target of PKG to mediate MLC 20 dephosphorylation and muscle relaxation. Smooth muscle cells were isolated from the circular muscle layer of rabbit stomach by sequential enzymatic digestion in 25 mM HEPES medium as described previously [25] by collagenase digestion. Dispersed muscle cells were harvested by filtration through 500-lm Nitex and then centrifuged twice at 3509g for 10 min. For permeabilization, dispersed smooth muscle cells were treated for 5 min with saponin (35 lg/ml) and resuspended in low-Ca 2? (100 nM) medium as previously described [26] . In some experiments, the cells were placed in culture in Dulbecco's modified Eagle's medium containing 10 % fetal bovine serum until they attained confluence [25] .
Materials and Methods

Materials
Transfection of M-RIP siRNA
The RNAi-Ready pSIREN-DNR-DsRed-Express Vector encoding M-RIP small-interfering RNA was inserted between BamH1 and EcoR1 restriction sites and transfected into cultured gastric smooth muscle cells with lipofectamine TM 2000 reagent according to the manufacturer's recommendation. To check the specificity of the siRNA, empty vector without the siRNA sequence was used as control. Successful knockdown of M-RIP protein was verified by Western blot and immunofluorescence microscopy [25] .
Phosphorylation of M-RIP
Phosphorylation of M-RIP was determined from the amount of 32 P incorporated by immunoprecipitation with specific antibody to M-RIP. Briefly, freshly dispersed cells were incubated with [ 32 P]orthophosphate for 4 h and samples (3 9 10 6 cells/ml) were then incubated with S-nitrosoglutathione (GSNO, 10 lM) or [8-(4-chlorophenylthio) guanosine 3 0 ,5 0 -cyclic monophosphate (8-pCPTcGMP, 10 lM) for 10 min in the presence or absence of PKG inhibitor guanosine 3 0 ,5 0 -cyclic monophosphorothioate, Rp isomer (Rp-cGMPS, 10 lM). Cell lysates were separated by centrifugation at 13,0009g for 10 min at 4°C, precleared with 40 ll of protein A-Sepharose, and incubated with M-RIP antibody for 2 h at 4°C and with 40 ll of protein A-Sepharose for another 1 h. The immunoprecipitates were extracted with Laemmli sample buffer and separated by electrophoresis on SDS-PAGE. After transfer to polyvinylidene difluoride (PVDF) membranes, [ 32 P]M-RIP was visualized by autoradiography, and the amount of radioactivity in the band was measured using liquid scintillation. The results were expressed as counts per minute per milligram of protein (cpm/mg protein) [25, 27] .
Phosphorylation of MLC 20
Permeabilized muscle cells were treated for 10 min with GSNO (10 lM) or cGMP (10 lM) followed by addition of Ca 2? (10 lM) for 30 s. Phosphorylation of MLC 20 was determined by immunoblot analysis using a phospho-Ser 19 -specific antibody as described previously [25] .
Immunoblot Analysis of M-RIP Association with MYPT1
Smooth muscle cells (3 9 10 6 cell/ml) were treated with GSNO (10 lM) or 8-pCPT-cGMP (10 lM) and the cell lysates were used to obtain MYPT1 immunoprecipitates. The immunoprecipitates were separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibody to M-RIP. After incubation with secondary antibody, the proteins were visualized. The intensity of the protein band on ECL film was determined using densitometry [27] .
Assay for Rho Kinase Activity
Rho kinase activity was measured by an immunokinase assay as previously described [25] . Twenty microliters of Rho kinase immunoprecipitates were added to the reaction mixture containing 100 mM Tris-HCl (pH 7.4), 1 M KCl, 50 mM MgCl 2 , 1 mM DTT, 1 mM ATP, and 10 lCi of [c-
32 P] ATP (3,000 Ci/mol) along with 5 lg of myelin basic protein, followed by incubation for 15 min at 37°C. Phosphorylation of myelin basic protein was measured by liquid scintillation. The results are expressed as counts per minute per milligram of protein.
Measurement of MLCP Activity
MLCP activity in myosin-enriched fractions prepared from permeabilized muscle cells was assayed using [ 32 P]-labeled MLC 20 as substrates [28] . [ 32 P]-labeled MLC 20 was prepared as described previously [29] by incubating MLC 20 (0.8 mg/ml) with purified MLCK (50 lg/ml), 0.1 mg/ml calmodulin, and 50 lmol/l [c-32 P]ATP.
Measurement of Contraction in Dispersed Smooth Muscle Cells
Permeabilized muscle cells were treated for 10 min with GSNO (10 lM) or cGMP (10 lM) followed by addition of Ca 2? (10 lM) for 30 s. The reaction was terminated with 1 % acrolein. The mean cell length of 50 muscle cells treated with Ca 2? alone or in the presence of GSNO or cGMP was measured using scanning micrometry and was compared with the length of untreated muscle cells (mean control cell length 96 ± 4 lm). Contraction was measured as decrease in muscle cell length in response to Ca 2? and relaxation was measured as inhibition of contraction [25, 26] .
Statistical Analysis
The results were expressed as means ± S.E. of n experiments and analyzed for statistical significance using Student's t test for paired and unpaired values. Each experiment was done on cells obtained from different animals. A probability of p \ 0.05 was considered significant.
Results
Selective Phosphorylation of M-RIP by PKG
Treatment of freshly dispersed smooth muscle cells with GSNO (10 lM) caused phosphorylation of M-RIP (3256 ± 502 cpm/mg protein compared to control phosphorylation of 425 ± 86 cpm/mg protein). M-RIP phosphorylation by GSNO was abolished by the selective PKG inhibitor Rp-cGMPS (10 lM, 82 ± 5 % inhibition) (Fig. 1a) suggesting that phosphorylation is mediated by PKG. Rp-cGMPS (10 lM) alone had no effect on basal M-RIP phosphorylation (483 ± 67 cpm/mg protein). Treatment of cells with a nonhydrolyzable membranepermeable analog of cGMP, 8-pCPT-cGMP (10 lM) that selectively activates PKG also induced phosphorylation of M-RIP (2865 ± 425 cpm/mg protein) and the extent of phosphorylation is similar to that induced by GSNO (Fig. 1a) . The effect of 8-pCPT-cGMP was inhibited by Rp-cGMPS (568 ± 102 cpm/mg protein).
Effect of PKG-Mediated Phosphorylation on Association of M-RIP with MYPT1
We examined whether phosphorylation by PKG augmented association of M-RIP with MYPT1 by immunoprecipitation of MYPT1 followed by Western blot analysis with M-RIP antibody. In the basal state M-RIP was associated with MYPT1. Rp-cGMPS (10 lM) alone had no effect on basal association of M-RIP with MYPT1 (data not shown). Treatment of cells with GSNO (10 lM) or 8-pCPT-cGMP (10 lM) increased the amount of MYPT1 associated with M-RIP. Increase in M-RIP association with MYPT1 by GSNO was abolished by the PKG inhibitor Rp-cGMPS (81 ± 4 % inhibition), suggesting that phosphorylation of M-RIP by PKG augmented the binding of M-RIP to MYPT1 (Fig. 1b) . Similar increase in association was obtained by immunoprecipitation of M-RIP followed by Western blot analysis with MYPT1 antibody (data not shown). (Fig. 2a) . Rp-cGMPS (10 lM) alone had no effect on basal MLCP activity (data not shown).
We also examined the increase in MLCP activity as inhibition of Ca Immunoprecipitates derived from 500 lg of protein using MYPT1 antibody were separated on SDS-PAGE and immunoblotted using M-RIP antibody. Rp-cGMPS (10 lM) alone had no effect on basal association of M-RIP with MYPT1 (data not shown). Values are mean ± SE of 4 experiments. ** p \ 0.01, significant increase in M-RIP and MYPT1 association (Fig. 2b) . Control studies showed that treatment of permeabilized cells with Ca 2? had no effect on Rho kinase activity (Fig. 3a) . In contrast, treatment of cells with the contractile agonist, acetylcholine caused stimulation of Rho kinase activity (Fig. 3a) .
Treatment of permeabilized smooth muscle cells with Ca 2? (10 lM) in the presence of Rho kinase inhibitor Y27632 (10 lM) caused contraction (32 ± 3 % decrease in cell length). Pretreatment of cells for 10 min with GSNO (10 lM) or cGMP (10 lM) inhibited Ca 2? -induced contraction (i.e., induced muscle relaxation) in a concentration-dependent manner (Fig. 3b) . These results suggest that inhibition of Ca 2? -induced MLC 20 phosphorylation and contraction by PKG was probably due to increased association of phosphorylated M-RIP with MYPT1 and subsequent stimulation of MLCP activity.
M-RIP-Dependent Inhibition of MLC 20 Phosphorylation
The specific involvement of M-RIP in PKG-mediated inhibition of MLC 20 phosphorylation was analyzed by transfection of cells with M-RIP siRNA. Western blot analysis revealed downregulation of M-RIP expression in cells transfected with M-RIP siRNA (Fig. 4) . Ca 2? -induced MLC 20 phosphorylation was not significantly affected (8 ± 5 % inhibition) by transfection of cells with M-RIP siRNA; however, GSNO-induced inhibition of MLC 20 phosphorylation was significantly attenuated (80 ± 8 % inhibition) by transfection of M-RIP siRNA (Fig. 4) .
Discussion
MLCP plays an important role in the regulation of MLC 20 phosphorylation and thus, smooth muscle contraction [5, 8, 30] . Contractile agonists induce MLC 20 phosphorylation and contraction with simultaneous inhibition of MLCP by phosphorylation of MYPT1 and CPI-17 [1, 2, 4, 5] . In contrast, relaxant agonists stimulate MLCP activity and induce MLC 20 dephosphorylation and relaxation via production of cAMP and cGMP and activation of PKA and PKG activity, respectively [2, 21, 31] . Inhibition of RhoA/ Rho kinase-dependent contraction by PKA and/or PKG reflects their action on various targets culminating in stimulation of MLCP activity. Three such targets have been identified: RhoA, telokin, and MYPT1 [1, [32] [33] [34] .
RhoA, via activation of Rho kinase and phosphorylation of the MYPT1, plays an important role in the smooth muscle contraction. Phosphorylation of MYPT1 at Thr 696 / Thr 853 by Rho kinase inhibits the activity of MLCP and promotes MLC 20 phosphorylation and contraction [1, 34] . Phosphorylaiton of RhoA (at Ser 188 ) by PKGIa, the main isoform of PKG in smooth muscle, and by PKA leads to translocation of RhoA and inhibition of Rho kinase activity [25, 32] . Recent studies have demonstrated that binding of activated PKGIa, but not inactive PKGIa to RhoA via leucine zipper domain is required for the inhibition of RhoA activity [35] . Telokin is an endogenous regulator of MLCP activity [33, 35] . Phosphorylation of telokin by PKA and PKG facilitates its interaction with phospho-MYPT1 (Thr 696 /Thr 853 ) and/or phospho MLC 20 to accelerate the dephosphorylation of the latter [1, 36] . MYPT1 is the targeting subunit of MLC phosphatase. Phosphorylation of MYPT1 at Ser 695 by PKG precludes inhibitory phosphorylation by Rho kinase and aids in disinhibition of MLCP activity [34] . A newly identified member of MYPT family, MYPT3, which lacks the C-terminal leucine zipper domain is phosphorylated by cAMP-dependent protein kinase leading to activation of the catalytic activity protein phosphatase 1 (PP1c) [37] . The functional significance of RhoA phosphorylation is well established, whereas the significance of MYPT1 and telokin phosphorylation remains to be determined.
Although M-RIP was initially isolated as a RhoA interacting protein, subsequent studies showed that under physiological conditions, M-RIP is not likely to interact directly with RhoA and regulate RhoA or Rho kinase activity [6, 14, 15] . The functional significance of M-RIP and RhoA association is unclear. The location of the scaffolding phosphoprotein M-RIP within the contractile filaments containing myosin and its interaction with the C-terminus leucine zipper domain of MYPT1, where PKGIa is shown to associate, makes it an ideal target of PKGIa, to modulate MLCP activity and MLC 20 dephosphorylation [17, 20, 31, 38] . We hypothesized that phos- and RhoA/Rho kinase. Permeabilization also excludes the possibility of telokin as one of the targets as treatment of cells with permeabilizing agents was shown to result in the loss of telokin from the cytosol into the extracellular medium [33] . However, the temporal relationship between M-RIP phosphorylation and MLCP activity was not examined. Thus, it is speculated that under these experimental conditions relaxation could be due to phosphorylation of M-RIP by PKG and activation of MLCP activity.
MLCP is a holoenzyme consisting of three subunits; a 20 kDa subunit of unknown function, an approximately 38 kDa catalytic subunit and a 130 kDa myosin targeting subunit (MYPT1). There are 4 distinct isoforms of MYPT1: 2 MYPT1 isoforms with inclusion or exclusion of 41 amino acid central insert, and 2 isoforms with inclusion (LZ ? MYPT1) and exclusion (LZ-MYPT1) of C-terminal leucine zipper domain [19, 20] . Previous studies showed requirement of LZ domain to interact with PKGIa and PKGIa-mediated phosphorylation of MYPT1 at Ser 695 [20, 22, 38] . Although the involvement of LZ domain of MYPT1 in the binding to PKGIa and M-RIP is established, direct interaction of PKGIa with M-RIP is not known. In summary, our results demonstrate that in gastrointestinal smooth muscle, M-RIP phosphorylation is mediated by PKG-Ia. Phosphorylation of M-RIP enhances its association with MYPT1 and MLC 20 dephosphorylation resulting in muscle relaxation. Given the complexity and the importance of MLCP, we provide evidence that M-RIP, which colocalizes with myosin and MYPT1 complex, is a target of PKG-Ia to regulate MLCP activity and muscle contraction. The present studies do not identify the singular contribution of M-RIP to mediate muscle relaxation in response to relaxant transmitters. It is possible that M-RIP along with other targets of PKG either cooperate dynamically to maintain muscle tone or serve as backup system under conditions where other systems are compromised. The importance of M-RIP to mediate muscle relaxation may depend on the expression levels. Recent studies have shown that the expression of M-RIP was higher in phasic (antrum) than tonic (fundus) muscle [39] . Further studies are needed to examine the physiological significance of M-RIP as regulator of MLCP activity in different regions of the gastrointestinal tract.
